Back to Newsroom

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 10/13/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed the Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). Corbus expects to report topline data from this study in the fourth quarter of 2016.

Click here to read the full release